Table 4.
T-cell receptor (TCR) Vβ usage ex vivo and following 28 days of in vitro expansion with anti-CD3 and recombinant human interleukin-2
| PID 23 |
PID 24 |
PID 25 |
PID 26 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TCR Usage | Day 0 | Day 28 | Ratio Day 28 : 0 | Day 0 | Day 28 | Ratio Day 28 : 0 | Day 0 | Day 28 | Ratio Day 28 : 0 | Day 0 | Day 28 | Ratio Day 28 : 0 |
| Vβ1 | 4·27 | 2·2 | 0·52 | 5·84 | 5·61 | 0·96 | 3·65 | 5·94 | 1·63 | 6·93 | 6·56 | 0·95 |
| Vβ2 | 3·02 | 0·78 | 0·26 | 6·69 | 5·55 | 0·83 | 3·56 | 6·59 | 1·85 | 3·38 | 5·21 | 1·54 |
| Vβ3 | 5·52 | 6·34 | 1·15 | 4·17 | 5·14 | 1·23 | 1·64 | 2·27 | 1·38 | 4·48 | 5·73 | 1·28 |
| Vβ4 | 0·64 | 6·24 | 9·751 | 1·51 | 3·41 | 2·26 | 1·26 | 1·72 | 1·37 | 0·85 | 0·66 | 0·78 |
| Vβ5.1 | 3·22 | 3·52 | 1·09 | 3·85 | 4·26 | 1·11 | 3·12 | 6·19 | 1·98 | 4·5 | 5·71 | 1·27 |
| Vβ5.2 | 1·44 | 1·43 | 0·99 | 0·79 | 0·91 | 1·15 | 1·3 | 1·59 | 1·22 | 1·8 | 1·56 | 0·87 |
| Vβ5.3 | 2·19 | 0·96 | 0·44 | 1·45 | 1·44 | 0·99 | 1·43 | 1·32 | 0·92 | 0·92 | 1·09 | 1·18 |
| Vβ7.1 | 3·42 | 3·23 | 0·94 | 2·23 | 2·41 | 1·08 | 2·17 | 3·93 | 1·81 | 1·73 | 2·56 | 1·48 |
| Vβ7.2 | 0·97 | 4·47 | 4·61 | 1·36 | 1 | 0·74 | 0·66 | 1·56 | 2·36 | 0·34 | 0·85 | 2·50 |
| Vβ8 | 3·86 | 4·54 | 1·18 | 3·96 | 4·43 | 1·12 | 4·24 | 4·67 | 1·10 | 4·6 | 4·99 | 1·08 |
| Vβ9 | 3·4 | 1·69 | 0·50 | 2·18 | 2·58 | 1·18 | 3·56 | 2·37 | 0·67 | 5·09 | 2·52 | 0·50 |
| Vβ11 | 0·95 | 1·54 | 1·62 | 1·06 | 1·33 | 1·25 | 1·07 | 1·32 | 1·23 | 0·4 | 1·22 | 3·05 |
| Vβ12 | 2·17 | 0·82 | 0·38 | 1·47 | 1·4 | 0·95 | 2·17 | 3·02 | 1·39 | 1·53 | 3·57 | 2·33 |
| Vβ13.1 | 6·15 | 0·81 | 0·13 | 2·96 | 3·69 | 1·25 | 3·2 | 4·82 | 1·51 | 4·27 | 4·98 | 1·17 |
| Vβ13.2 | 1·3 | 1·41 | 1·08 | 2·62 | 2·61 | 1·00 | 1·24 | 1·59 | 1·28 | 0·97 | 1·66 | 1·71 |
| Vβ13.6 | 1·97 | 3·03 | 1·54 | 2·31 | 2·43 | 1·05 | 1·74 | 3·19 | 1·83 | 0·89 | 2·3 | 2·58 |
| Vβ14 | 2·72 | 2·73 | 1·00 | 10·55 | 11·1 | 1·05 | 6·27 | 4·24 | 0·68 | 3·15 | 3·52 | 1·12 |
| Vβ16 | 2·36 | 2·39 | 1·01 | 0·93 | 0·95 | 1·02 | 1·59 | 3·18 | 2·00 | 1·27 | 2·4 | 1·89 |
| Vβ17 | 2·54 | 4·06 | 1·60 | 3·57 | 3·8 | 1·06 | 2·47 | 6·23 | 2·52 | 5·96 | 4·39 | 0·74 |
| Vβ18 | 0·64 | 0·55 | 0·86 | 0·36 | 0·46 | 1·28 | 0·56 | 0·62 | 1·11 | 0·81 | 0·96 | 1·19 |
| Vβ20 | 3·03 | 3·37 | 1·11 | 2 | 2·41 | 1·21 | 2·61 | 3·48 | 1·33 | 2·38 | 3·19 | 1·34 |
| Vβ21.3 | 5·42 | 5·48 | 1·01 | 0·55 | 0·87 | 1·58 | 2·64 | 4·42 | 1·67 | 1·99 | 4·17 | 2·10 |
| Vβ22 | 2·55 | 5·16 | 2·02 | 3·87 | 3·94 | 1·02 | 2·43 | 4·68 | 1·93 | 3·54 | 3·94 | 1·11 |
| Vβ23 | 2 | 4·59 | 2·30 | 0·64 | 0·56 | 0·88 | 0·82 | 1·18 | 1·44 | 0·94 | 1·25 | 1·33 |
| Mean | 1·55 | 1·14 | 1·51 | 1·46 | ||||||||
| Pearson R-value | 0·18202 | 0·9736 | 0·6896 | 0·8408 | ||||||||
| Pearson P-value | 0·3946 | < 0·0001 | 0·0002 | < 0·0001 | ||||||||
1
Changes in any Vβ subset from day 28 to day 0 that were > 2 are denoted in bold.
2
The correlation between Vβ TCR usage at day 0 and day 28 was tested using a Pearson test and R-values and P-values are shown.